We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Reneuron Group | AQSE:RENE.GB | Aquis Stock Exchange | Ordinary Share | GB00BF5G6K95 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 0.00 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2022 to May 2024
TIDMRENE
RNS Number : 9328P
ReNeuron Group plc
15 February 2023
ReNeuron Group plc
("ReNeuron" or "the Company" or "the Group")
Grant of Options
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies , announces that grants were made on 14 February 2023 for options over 4,030,000 Ordinary Shares of 1p each ("Options") under the terms of the Company's Long Term Incentive Plan ("The Plan") and its Non-Executive Share Option Scheme. The grants of 3,000,000 Options made to Directors and Persons Discharging Managerial Responsibilities (PDMRs) are set out further in the table below.
1,615,000 of the Options granted under The Plan have an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days.
The remaining 1,415,000 of the Options granted under The Plan have an exercise price of 31.5 pence per share. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. None of these Options are subject to any further performance conditions.
The 1,000,000 Options granted to Iain Ross are granted under the Non-Executive Share Option Scheme. 750,000 of the Options are granted with an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days. 250,000 of the Options are granted with an exercise price of 50.0 pence per share without any further performance conditions. All of Mr Ross's options vest monthly over three years on a straight-line basis.
Hot Features
Premium
Name Title Date of grant Number Total shares Percentage
of Options of Options over which of issued
granted options shares under
are held option
(post award)
14 February
Iain Ross Executive Chairman 2023 1,000,000 1,500,000 2.62%
-------------------- --------------- ------------ -------------- --------------
Chief Financial 14 February
John Hawkins Officer 2023 500,000 840,000 1.47%
-------------------- --------------- ------------ -------------- --------------
Chief Scientific 14 February
Randolph Corteling Officer 2023 500,000 1,000,000 1.75%
-------------------- --------------- ------------ -------------- --------------
Chief Business 14 February
Simon Dew Officer 2023 600,000 600,000 1.05%
-------------------- --------------- ------------ -------------- --------------
Chief Operations 14 February
Suzanne Hancock Officer 2023 400,000 749,326 1.31%
-------------------- --------------- ------------ -------------- --------------
S
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3100 2000
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804
654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX(TM) platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to grant of share options to Directors and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Iain Ross
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Executive Chairman
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 1,000,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 F e bruary 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name John Hawkins
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 500,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 February 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Randolph Corteling
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 500,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 February 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Simon Dew
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Business Officer
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 600,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 F ebruary 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Suzanne Hancock
------------------------------------ -----------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Head of Operations
------------------------------------ -----------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
------------------------------------ -----------------------------------
b) LEI 2138003TU12CQ5TZO137
------------------------------------ -----------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
------------------------------------ -----------------------------------
b) Nature of the transaction Grant of share options
------------------------------------ -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.00 400,000
------------------------------------ -----------------------------------
d) Aggregated information N/A
------------------------------------ -----------------------------------
e) Date of the transaction 14 February 2023
------------------------------------ -----------------------------------
f) Place of the transaction Outside of a trading venue
------------------------------------ -----------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKZLFFXLLZBBD
(END) Dow Jones Newswires
February 15, 2023 02:00 ET (07:00 GMT)
1 Year Reneuron Chart |
1 Month Reneuron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
